Literature DB >> 15889278

A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy.

Kunihiko Takahashi1, Shigetoyo Kogaki, Shunji Kurotobi, Sayaka Nasuno, Makiko Ohta, Hitomi Okabe, Kazuko Wada, Norio Sakai, Masako Taniike, Keiichi Ozono.   

Abstract

UNLABELLED: A male infant with clinical features of Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy is reported. He manifested severe heart failure and failure to thrive. Administration of propranolol and cibenzoline improved ventricular outflow tract obstruction, leading to catch-up growth. Genetic analysis of the patient revealed a novel missense mutation in the PTPN11 gene.
CONCLUSION: This is the first description of a patient with a Gln510Glu mutation in the protein-tyrosine phosphatase, non-receptor type 11 gene. This specific mutation may be associated with a rapidly progressive hypertrophic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15889278     DOI: 10.1007/s00431-005-1679-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  21 in total

1.  PTPN11 (protein-tyrosine phosphatase, nonreceptor-type 11) mutations in seven Japanese patients with Noonan syndrome.

Authors:  Kenjiro Kosaki; Taichi Suzuki; Koji Muroya; Tomonobu Hasegawa; Seiji Sato; Nobutake Matsuo; Rika Kosaki; Toshiro Nagai; Yukihiro Hasegawa; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

Review 2.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

3.  Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes.

Authors:  A Sarkozy; E Conti; D Seripa; M C Digilio; N Grifone; C Tandoi; V M Fazio; V Di Ciommo; B Marino; A Pizzuti; B Dallapiccola
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

4.  Congenital heart diseases in children with Noonan syndrome: An expanded cardiac spectrum with high prevalence of atrioventricular canal.

Authors:  B Marino; M C Digilio; A Toscano; A Giannotti; B Dallapiccola
Journal:  J Pediatr       Date:  1999-12       Impact factor: 4.406

5.  PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.

Authors:  Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2002-05-01       Impact factor: 11.025

6.  Rapidly progressive obstructive cardiomyopathy in infants with Noonan's syndrome. Report of two cases.

Authors:  H D Hirsch; H Gelband; O Garcia; S Gottlieb; D M Tamer
Journal:  Circulation       Date:  1975-12       Impact factor: 29.690

7.  Identification of a putative Syp substrate, the PDGF beta receptor.

Authors:  R A Klinghoffer; A Kazlauskas
Journal:  J Biol Chem       Date:  1995-09-22       Impact factor: 5.157

8.  Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.

Authors:  Alessandra Fragale; Marco Tartaglia; Jie Wu; Bruce D Gelb
Journal:  Hum Mutat       Date:  2004-03       Impact factor: 4.878

9.  Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes.

Authors:  Yoshikazu Nakaoka; Keigo Nishida; Yasushi Fujio; Masahiro Izumi; Kazuo Terai; Yuichi Oshima; Shoko Sugiyama; Satoshi Matsuda; Shigeo Koyasu; Keiko Yamauchi-Takihara; Toshio Hirano; Ichiro Kawase; Hisao Hirota
Journal:  Circ Res       Date:  2003-07-10       Impact factor: 17.367

10.  Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses.

Authors:  U Schaeper; N H Gehring; K P Fuchs; M Sachs; B Kempkes; W Birchmeier
Journal:  J Cell Biol       Date:  2000-06-26       Impact factor: 10.539

View more
  19 in total

1.  Elevated Ca2+ transients and increased myofibrillar power generation cause cardiac hypercontractility in a model of Noonan syndrome with multiple lentigines.

Authors:  Sarah A Clay; Timothy L Domeier; Laurin M Hanft; Kerry S McDonald; Maike Krenz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-02-27       Impact factor: 4.733

2.  PTPN11 gene mutations: linking the Gln510Glu mutation to the "LEOPARD syndrome phenotype".

Authors:  M Cristina Digilio; Anna Sarkozy; Giuseppe Pacileo; Giuseppe Limongelli; Bruno Marino; Bruno Dallapiccola
Journal:  Eur J Pediatr       Date:  2006-05-30       Impact factor: 3.183

3.  Heterozygous deletion of AKT1 rescues cardiac contractility, but not hypertrophy, in a mouse model of Noonan Syndrome with Multiple Lentigines.

Authors:  Rajika Roy; Maike Krenz
Journal:  J Mol Cell Cardiol       Date:  2017-09-11       Impact factor: 5.000

4.  Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals.

Authors:  Helen He Zhu; Xiaolin Luo; Kaiqing Zhang; Jian Cui; Huifang Zhao; Zhongzhong Ji; Zhicheng Zhou; Jufang Yao; Lifan Zeng; Kaihong Ji; Wei-Qiang Gao; Zhong-Yin Zhang; Gen-Sheng Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

5.  PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.

Authors:  Rebecca J Chan; Gen-Sheng Feng
Journal:  Blood       Date:  2006-10-19       Impact factor: 22.113

Review 6.  The cardiofaciocutaneous syndrome.

Authors:  A Roberts; J Allanson; S K Jadico; M I Kavamura; J Noonan; J M Opitz; T Young; G Neri
Journal:  J Med Genet       Date:  2006-07-06       Impact factor: 6.318

7.  Effect of cibenzoline on biventricular pressure gradients in a pediatric patient with hypertrophic obstructive cardiomyopathy.

Authors:  Takamichi Ishikawa; Satoru Iwashima; Takehiko Ohzeki
Journal:  Pediatr Cardiol       Date:  2010-02-07       Impact factor: 1.655

8.  Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: palliative treatment with a rapamycin analog.

Authors:  Andreas Hahn; Jessica Lauriol; Josef Thul; Kachina Behnke-Hall; Tushiha Logeswaran; Anne Schänzer; Nuray Böğürcü; Boyan K Garvalov; Martin Zenker; Bruce D Gelb; Susanne von Gerlach; Reinhard Kandolf; Maria I Kontaridis; Dietmar Schranz
Journal:  Am J Med Genet A       Date:  2015-02-23       Impact factor: 2.802

9.  New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.

Authors:  Christine Schramm; Michelle A Edwards; Maike Krenz
Journal:  J Biol Chem       Date:  2013-05-14       Impact factor: 5.157

10.  PTPN11 gene mutation and severe neonatal hypertrophic cardiomyopathy: what is the link?

Authors:  Maria Felicia Faienza; Lucia Giordani; Marina Ferraris; Gianni Bona; Luciano Cavallo
Journal:  Pediatr Cardiol       Date:  2009-07-07       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.